Abstract 501P
Background
Previous studies have proved that EGFR exon 20 insertion (EGFRex20ins) mutation present in about 1.8% of non-small cell lung cancer (NSCLC). 22% of EGFRex20ins are co-occurring with EGFR amplification. The aim of this study is to investigate the clinical characteristics and efficacy in Chinese NSCLC patients harboring EGFRex20ins and EGFR amplification.
Methods
A total of 1483 patients with advanced NSCLC were screened. All variants of EGFRex20ins and other oncogenic drivers were identified by next-generation sequencing (NGS).
Results
EGFRex20ins were found in 2.2% of patients and a total of 38 patients were included in clinical characteristics analysis. Various EGFRex20ins were identified, most commonly V769_D770dup (26.3%) and D770_N771dup (23.7%). Interestingly, co-occurring EGFR amplification was found in 39.5% of patients (15/38). In patients with EGFR amplification, the median age was 58 years (range, 38 to 75 years), and 66.7% were female. Most of them were never-smokers (86.7%) and had adenocarcinoma (93.3%). These clinical characteristics were not significantly different from those without EGFR amplification (P > 0.05). Except for patients with EGFR-sensitive mutations, a total of 25 patients who had used EGFR-tyrosine kinase inhibitors (TKIs) were included in the survival analysis. Although there were no statistically differences in two group, a tendency of prolonged median progression-free survival (mPFS) in patients without EGFR amplification was found (80.5 versus 30.0 days, P = 0.175).
Conclusions
EGFR amplification often co-occur with EGFRex20ins in Chinese NSCLC, and the ratio is higher than previous studies in Caucasian. Although there was no difference in clinical characteristics and efficacy between patients with and without EGFR amplification, a tendency of prolonged mPFS in patients without EGFR amplification was found. Future prospectively large-sample-size studies are needed to evaluate this finding.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Guangdong Lung Cancer Institute.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
436P - Assessing the quality of life of Filipino cancer patients: A survey of Filipino oncologists
Presenter: Frederic Ivan Ting
Session: Poster display session
Resources:
Abstract
437P - Correlation between bio-impedance analysis and abdominal CT scan to diagnose decreased muscle mass in adult cancer patients
Presenter: Andree Kurniawan
Session: Poster display session
Resources:
Abstract
438P - Evaluating mitochondrial biomarkers between fatigue subclasses identified using latent class analysis in early-stage breast cancer patients
Presenter: Yi Long Toh
Session: Poster display session
Resources:
Abstract
440P - Accuracy of risk scoring system to determine delayed chemotherapy induced nausea and vomiting (CINV) in cancer patients
Presenter: Jada Harika
Session: Poster display session
Resources:
Abstract
441P - A pilot cross-sectional study on incidence of liver toxicity in cancer patients on western anti-cancer drug therapy with or without concurrent Chinese herbal medicine
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
442P - Relationship between QOL and support elderly patients with permanent colostomies
Presenter: Yukiko Orii
Session: Poster display session
Resources:
Abstract
443P - The effectiveness of individual nutritional counselling for patients with advanced cancer undergoing chemotherapy: A preliminary study
Presenter: Saori Koshimoto
Session: Poster display session
Resources:
Abstract
444P - The prophylactic effect of 0.1% fluorometholone eye drops on eye disorders caused by high-dose cytarabine
Presenter: Takayuki Tsuchiya
Session: Poster display session
Resources:
Abstract
445P - Safety and feasibility of extending flushing interval every 3 months for maintenance of TICVPS in CRC patients after completion of curative intended treatments
Presenter: Sang Bo Oh
Session: Poster display session
Resources:
Abstract
446P - Accuracy of risk scoring system to determine chemotherapy induced nausea and vomiting (CINV) in cancer patients receiving first cycle chemotherapy
Presenter: Jada Harika
Session: Poster display session
Resources:
Abstract